Chronic Obstructive Pulmonary Disease (COPD) Market Size was valued at USD 20.84 billion in 2023 and is projected to grow from USD 22.07 Billion in 2024 to USD 33.72 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.82% during the forecast period (2024 - 2032). Rise in prevalence of CPOD across the globe and the increase in adoption of more effective combination therapy are driving the market growth.
Breathing problems are caused by various lung diseases known as chronic obstructive pulmonary disease. The two main chronic obstructive pulmonary disorders categories are emphysema and chronic bronchitis. One of the main signs of COPD is difficulty breathing. One significant element anticipated to accelerate the development and customer demand of the chronic obstructive pulmonary disease industry is the increase in COPD cases among populations worldwide. Additionally, throughout the forecast period, the global market is anticipated to grow due to an increase in cigarette usage among young people and a general increase in public awareness of the benefits of using generic medications.
Additionally, increased healthcare spending is offering facilities for COPD in developing nations, and increased public awareness throughout developing and underdeveloped regions is also projected to support the market's expansion. Furthermore, one of the important factors anticipated to propel the advancement of the chronic obstructive pulmonary disease industry is the rise in R&D expenditure by the government and major companies. The lungs' alveoli are harmed in emphysema cases. As a result of the stretched alveolar walls, the lungs get larger, and the airflow becomes more challenging. The bronchial airways in the lungs become irritated when bronchitis is chronic.
Globally high COPD prevalence and a strong pipeline of COPD therapy medications are expected to drive the market throughout the forecast period. Furthermore, the chronic obstructive pulmonary disease treatment industry is expected to grow quickly due to the rise in elderly people and bad lifestyle choices made by people of all ages. Most COPD treatments concentrate on symptom management and delaying the onset of the disease. Still, there is a critical need for fresh, cutting-edge treatments that would benefit patients more and enhance their standard of life. Research and development have lately concentrated on brand-new COPD remedies, including gene therapies, biologics, and other cutting-edge methods. These treatments may target the root causes of COPD and offer patients more efficient and focused care.
Chronic obstructive pulmonary disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management. Tobacco smoking could lead to COPD. The number of adults addicted to smoking has been increasing across the globe. Other risk factors include occupation and indoor air pollution. According to the World Health Organization (WHO), the primary cause of COPD is exposure to tobacco smoke. According to the organization, chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, accounting for 3.23 million deaths in 2022. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC).
The Chronic Obstructive Pulmonary Disease Treatment (COPD) market segmentation, based on type, includes Emphysema, and Chronic Bronchitis. The chronic bronchitis segment held the majority share in 2021 in respect to the Chronic Obstructive Pulmonary Disease Treatment (COPD) market revenue. This is primarily owing to the growing incidence and prevalence of chronic bronchitis worldwide due to the rise in the consumption of cigarettes and the increase in industrialization, which results in air pollution and the release of harmful gases into the environment.
June 2022:AstraZeneca announced a plan to build a manufacturing unit in Qingdao, China, to produce its Breztri aerosol inhalant COPD treatment, which was recently added to the country’s National Reimbursement Drug List. Also, the company announced (in Chinese) during a meeting with local community officials but did not provide details on cost, scale, or completion date. Additionally, AstraZeneca said, that it would set up a regional headquarters in Qingdao and an innovation center focusing on rare diseases as part of its efforts to promote biomedical innovation in Qingdao.
July 2021:AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been approved and granted Priority Review for the treatment of asthma by the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.
The Chronic Obstructive Pulmonary Disease Treatment (COPD) market segmentation, based on treatment type, includes drugs, surgery, and oxygen therapy. The drugs segment held the majority share in 2021 in respect to the Chronic Obstructive Pulmonary Disease Treatment (COPD) market revenue. This is primarily owing to the increasing use of drugs as the first line of treatment for COPD to make breathing easier by widening airways. Additionally, it is bifurcated into bronchodilator monotherapy, and anti-inflammatory drugs. Bronchodilator monotherapy further bifurcated into Short-Acting Beta2-Agonists (SABAs), Long-Acting Beta2-Agonists (LABAs), and anti-inflammatory drugs further bifurcated into oral and inhaled corticosteroids, and anti-leukotrienes.
Moreover, the oxygen therapy market is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the factors such as the rapid growth of the geriatric population the development of respiratory disorders, the rising prevalence of tobacco smoking, the increase in the usage of home-based oxygen therapy, and technological advancements. Hence, rising treatment of Chronic Obstructive Pulmonary Disease Treatment (COPD) positively impacts the market growth.
The Chronic Obstructive Pulmonary Disease (COPD) market data has been bifurcated by surgery into hospitals & clinics, homecare settings, and others. The hospital & clinics segment dominated the market in 2021. This is primarily owing to the growing number of patients suffering from chronic respiratory diseases and rising awareness about these diseases. Furthermore, the availability of various diagnostics and treatment facilities and higher purchasing power has contributed to the segment’s growth.
November 2021:AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for USD 270 Million. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).
Figure 2: Chronic Obstructive Pulmonary Disease Treatment (COPD) Market, by End User, 2021 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
News:
More than 40% of the tiniest airways in people's lungs have already been destroyed by the time moderate chronic obstructive pulmonary disease, a condition that prevents airflow in the lungs, is identified. The cells causing this damage to the tiny airways have been identified by a recent UBC faculty of medicine study in the American Journal of Respiratory and Critical Care Medicine. According to the research, people with COPD gradually lose the alveolar attachments that open their small airways. Dr. Hackett and her team conducted high-resolution imaging investigations to examine small airway illness at the single-cell level using lung tissue samples from 40 patients with COPD for the lung biobank at St. Paul's Hospital.
By Region, the study segments the market into North America, Europe, Asia-Pacific and Rest of the World. North America Chronic Obstructive Pulmonary Disease Treatment (COPD) held the largest market share in 2021. This is attributed to the increased investment in R&D activities to develop innovative drugs for treating diseases. Also, the rise in incidence and prevalence of chronic respiratory diseases, technological advancement, growing healthcare sectors, and massive presence of leading market players are some of the major factors that boost the COPD Market in the region.
Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT (COPD) MARKET SHARE BY REGION 2021 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Chronic Obstructive Pulmonary Disease Treatment (COPD) market accounts for the second-largest market share due to the well-developed healthcare infrastructure and an increase in the incidence of chronic obstructive pulmonary diseases are propelling the COPD treatment market in the region. Further, the Germany Chronic Obstructive Pulmonary Disease Treatment (COPD) market held the largest market share, and the UK Chronic Obstructive Pulmonary Disease Treatment (COPD) market was the fastest growing market in the European region.
The Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment (COPD) market is expected to grow with a significant share. This is due to the untapped chronic obstructive pulmonary disease treatment market compared to developed regions. Therefore, Asia Pacific offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the chronic obstructive pulmonary disease treatment market in the region.
Moreover, China Chronic Obstructive Pulmonary Disease Treatment (COPD) market held the largest market share, and the India Chronic Obstructive Pulmonary Disease Treatment (COPD) market was the fastest growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2024–2032.
Chronic Obstructive Pulmonary Disease Treatment (COPD) Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the Chronic Obstructive Pulmonary Disease Treatment (COPD) market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Chronic Obstructive Pulmonary Disease (COPD) industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the Chronic Obstructive Pulmonary Disease Treatment (COPD) industry to benefit clients and expand the Chronic Obstructive Pulmonary Disease Treatment (COPD) market sector is to manufacture locally to reduce operating costs. In recent years, Chronic Obstructive Pulmonary Disease (COPD) has provided medicine with some of the most significant benefits.
Alembic Pharmaceuticals Ltd. is a leading pharmaceutical company committed to develop, manufacture and market pharmaceutical products, pharmaceutical substances, and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs. In May 2022, Alembic Pharmaceuticals Ltd., a pharmaceutical company, received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.
Key Companies in the Chronic Obstructive Pulmonary Disease Treatment (COPD) market includes
Chronic Obstructive Pulmonary Disease (COPD) Industry Developments
October 2021:Mylan Pharmaceuticals received the FDA approval for its investigational new drug application (ANDA) for Breyna. The first approved generic version of AstraZeneca's. It is also anticipated to be available in dosage strengths of 160 mcg/4.5 mcg and 80 mcg/4.5 mcg for patients with asthma or chronic obstructive pulmonary disease (COPD).
January 2019:CHIESI Farmaceutici S.p.A. entered into an exclusive license agreement with TiumBio, a clinical-stage private biotech company based in South Korea. TiumBio specializes in research on innovative drugs for rare diseases. The agreement is aimed at developing innovative molecules for usage in the treatment of respiratory diseases.
June 2022:Verona Pharma, announced the completion of the patient enrolment, with more than 800 subjects involved in its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.
Oxygen Therapy
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 20.84 billion |
| Market Size 2024 | USD 22.07 billion |
| Market Size 2032 | USD 33.72 billion |
| Compound Annual Growth Rate (CAGR) | 4.82% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2018 & 2020 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment Type, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | AstraZeneca (UK), Abbott Laboratories (US), Dr. Reddy’s Laboratories Ltd (India), GlaxoSmithKline (UK), F. Hoffmann-La Roche Ltd (Switzerland), Almirall (Spain), Boehringer Ingelheim (Germany), Pfizer Inc. (US), Novartis AG (Switzerland), Astellas Pharma (Japan) |
| Key Market Opportunities | Increasing demand for home care therapeutic devices |
| Key Market Dynamics | Rise in prevalence of CPOD across the globe Increase in adoption of more effective combination therapy |
Frequently Asked Questions (FAQ) :
The Chronic Obstructive Pulmonary Disease Treatment (COPD) market is anticipated to reach USD 33.72 billion at a CAGR of 4.82% during the forecast period of 2024 to 2032
The U.S Chronic Obstructive Pulmonary Disease Treatment (COPD) market share is 35-40% during the forecast period of 2024 to 2032
The Chronic Obstructive Pulmonary Disease Treatment (COPD) market is expected to register a CAGR of 4.82% during the forecast period of 2024 to 2032.
The North America held the largest market share in the Chronic Obstructive Pulmonary Disease Treatment (COPD) market
AstraZeneca (UK), Abbott Laboratories (US), Dr. Reddy’s Laboratories Ltd (India), GlaxoSmithKline (UK), and F. Hoffmann-La Roche Ltd (Switzerland)
The drugs segment led the Chronic Obstructive Pulmonary Disease Treatment (COPD) market
The Hospitals & Clinics end user led the Chronic Obstructive Pulmonary Disease Treatment (COPD) market
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
